Abstract
Retrospective evidence suggests that patients with high grade ovarian cancer (HGOC) progressing to PARP inhibitors (PARPi) might be less likely to response to platinum therapy. The aim of our study was to assess in preclinical models if trabectedin will be an active agent in carboplatin-and PARPi-resistant HGOC cell lines.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
